Guggenheim maintains Beam Therapeutics at Buy, lowers price target to $51 from $55
Guggenheim kept its Buy rating on Beam Therapeutics but reduced its price target to $51 from $55, a 7.3% decrease. The new target suggests an 83.5% upside from the Nov 4 close of $27.79. Recent analyst notes on the company have price targets ranging from $30 to $80.
How this was made

The 30-second read
Why it matters
The target cut reflects revised expectations for Beam Therapeutics' near‑term performance, likely prompting a modest sell‑off.
Market read
Analyst target reduction is a fresh piece of information that can influence trader decisions on BEAM today.
What to watch
Potential upcoming clinical data or partnership announcements could offset the target reduction.
Background
Analyst price‑target adjustments are a common catalyst for short‑term price moves in biotech stocks.
Ticker impact
Guggenheim lowered Beam Therapeutics price target to $51 from $55, maintaining a Buy rating.
likely downward pressure as the market prices in the reduced target
Target reduction of ~7% signals weaker expectations, prompting short‑term sell pressure.
Market effects
May temper enthusiasm for the broader gene‑editing biotech sector.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Despite the target cut, the Buy rating remains, suggesting upside if the market overreacts.
Key entities
- Analyst FirmGuggenheim
Equity research firm providing the rating and price target.
- CompanyBeam Therapeutics
US‑listed biotech focused on gene‑editing technologies.
